Biopharmaceutical company Suven Life Sciences, which is looking at raising about Rs 90 crore, is participating at the 29th JP Morgan Healthcare Conference being held at San Francisco, US, from January 10 to 13.
The company will explain business strategy, fund raising and partnering activities for its SUVN-502, which is ready for Phase IIa clinical studies. This is useful in dealing with Alzheimer’s and Schizophrenia, according to its chief executive officer Venkat Jasti.
The market potential of unmet medical needs in the central nervous system disorders segment is estimated at $20 billion. JP Morgan Healthcare Conference brings investment professionals and innovation companies on a common platform, a company release said here on Tuesday.